Fra‑1 is downregulated in cervical cancer tissues and promotes cervical cancer cell apoptosis by p53 signaling pathway in vitro

Xiao,Songshu; Zhou,Yanhong; Yi,Wei; Luo,Guijuan; Jiang,Bin; Tian,Qi; Li,Yueran; Xue,Min

doi:10.3892/ijo.2015.2873

Fra‑1 is downregulated in cervical cancer tissues and promotes cervical cancer cell apoptosis by p53 signaling pathway in vitro

Authors:
- Songshu Xiao
- Yanhong Zhou
- Wei Yi
- Guijuan Luo
- Bin Jiang
- Qi Tian
- Yueran Li
- Min Xue
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China, Cancer Research Institute, Central South University, Changsha, Hunan 410078, P.R. China
Published online on: February 4, 2015 https://doi.org/10.3892/ijo.2015.2873
Pages: 1677-1684

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer is a potentially preventable disease; however, it is the third most commonly diagnosed cancer and the fourth leading cause of cancer deaths in women worldwide. Cervical cancer is thought to develop through a multistep process involving virus, tumor suppressor genes, proto‑oncogenes and immunological factors. It is known that human papillomavirus (HPV) infection is necessary but insufficient to cause malignancy. At present, the etiology of cervical carcinoma remains poorly understood. In this study, we found that the expression of FOS‑like antigen‑1 (Fra‑1) gene was downregulated in cervical cancer compared with the adjacent non‑cancerous tissues by RT‑qPCR, immunohistochemistry (IHC) and western blotting techniques. To uncover the effect of Fra‑1 on cervical cancer, we tested and confirmed that Fra‑1 significantly inhibited the proliferation of HeLa cells by MMT assays in vitro. At the same time, overexpression of Fra‑1 promoted apoptosis of HeLa cells. To explore the possible mechanism of Fra‑1 in cervical cancer, we tested the expression levels of key molecules in p53 signaling pathway by western blotting technology. The results showed that p53 was downregulated in cervical cancer compared with the adjacent non‑cancerous tissues, but MDM2 proto‑oncogene, E3 ubiquitin protein ligase (MDM2) was upregulated in cervical cancer. In vitro, the p53 was upregulated and MDM2 was downregulated in HeLa cells with Fra‑1 overexpression. In summary, our results suggested that Fra‑1 expression is low in cervical cancer tissues and promotes apoptosis of cervical cancer cells by p53 signaling pathway.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Boutas I, Sofoudis C, Kalampokas E, Anastasopoulos C, Kalampokas T and Salakos N: Fertility preservation in women with early stage cervical cancer. Review of the literature. Eur J Gynaecol Oncol. 35:373–377. 2014.PubMed/NCBI
3	He L, Wu L, Su G, Wei W, Liang L, Han L, Kebria M, Liu P, Chen C, Yu Y, Zhong M and Wang W: The efficacy of neoadjuvant chemotherapy in different histological types of cervical cancer. Gynecol Oncol. 134:419–425. 2014. View Article : Google Scholar : PubMed/NCBI
4	Georgieva S, Iordanov V and Sergieva S: Nature of cervical cancer and other HPV-associated cancers. J BUON. 14:391–398. 2009.PubMed/NCBI
5	Lazcano-Ponce E and Allen-Leigh B: Innovation in cervical cancer prevention and control in Mexico. Arch Med Res. 40:486–492. 2009. View Article : Google Scholar : PubMed/NCBI
6	Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W and zur Hausen H: A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 3:1151–1157. 1984.PubMed/NCBI
7	Dürst M, Gissmann L, Ikenberg H and zur Hausen H: A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA. 80:3812–3815. 1983. View Article : Google Scholar : PubMed/NCBI
8	Cheng JX, Yuan M, Li AL, Zhou P, Shen GQ and Zhang Y: Quantitative analysis of P16 gene CpG methylation in Uyghur patients with cervical squamous cell carcinoma and its relationship with HPV16 infection. Genet Mol Res. 13:7428–7436. 2014. View Article : Google Scholar : PubMed/NCBI
9	Andersson S, Mints M, Gyllensten U, Lindell M, Gustavsson I, Lambe M and Wilander E: Uneven distribution of human papillomavirus 16 in cervical carcinoma in situ and squamous cell carcinoma in older females: A retrospective database study. Oncol Lett. 8:1528–1532. 2014.PubMed/NCBI
10	McLaughlin-Drubin ME and Munger K: Viruses associated with human cancer. Biochim Biophys Acta. 1782:127–150. 2008. View Article : Google Scholar : PubMed/NCBI
11	Deivendran S, Marzook KH and Radhakrishna Pillai M: The role of inflammation in cervical cancer. Adv Exp Med Biol. 816:377–399. 2014. View Article : Google Scholar : PubMed/NCBI
12	Ramdass B, Chowdhari A and Koka P: Cancer-initiating cells as target for prevention of recurring disease etiology: role of these malignant putative progenitor cells in relapse or metastasis of human cervical carcinoma. J Stem Cells. 8:233–251. 2013.
13	Luo Y, Zhou H, Mizutani M, Mizutani N, Reisfeld RA and Xiang R: Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine. Proc Natl Acad Sci USA. 100:8850–8855. 2003. View Article : Google Scholar : PubMed/NCBI
14	Luo Y, Zhou H, Mizutani M, Mizutani N, Liu C, Xiang R and Reisfeld RA: A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence. Cancer Res. 65:3419–3427. 2005.PubMed/NCBI
15	Cohen DR and Curran T: fra-1: a serum-inducible, cellular immediate-early gene that encodes a fos-related antigen. Mol Cell Biol. 8:2063–2069. 1988.PubMed/NCBI
16	Schreiber M, Poirier C, Franchi A, Kurzbauer R, Guenet JL, Carle GF and Wagner EF: Structure and chromosomal assignment of the mouse fra-1 gene, and its exclusion as a candidate gene for oc (osteosclerosis). Oncogene. 15:1171–1178. 1997. View Article : Google Scholar : PubMed/NCBI
17	Desmet CJ, Gallenne T, Prieur A, Reyal F, Visser NL, Wittner BS, Smit MA, Geiger TR, Laoukili J, Iskit S, Rodenko B, Zwart W, Evers B, Horlings H, Ajouaou A, Zevenhoven J, van Vliet M, Ramaswamy S, Wessels LF and Peeper DS: Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci USA. 110:5139–5144. 2013. View Article : Google Scholar : PubMed/NCBI
18	Lu D, Chen S, Tan X, Li N, Liu C, Li Z, Liu Z, Stupack DG, Reisfeld RA and Xiang R: Fra-1 promotes breast cancer chemo-sensitivity by driving cancer stem cells from dormancy. Cancer Res. 72:3451–3456. 2012. View Article : Google Scholar : PubMed/NCBI
19	Casalino L, De Cesare D and Verde P: Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization. Mol Cell Biol. 23:4401–4415. 2003. View Article : Google Scholar : PubMed/NCBI
20	Zippo A, De Robertis A, Serafini R and Oliviero S: PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol. 9:932–944. 2007. View Article : Google Scholar : PubMed/NCBI
21	Casalino L, Bakiri L, Talotta F, Weitzman JB, Fusco A, Yaniv M and Verde P: Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription. EMBO J. 26:1878–1890. 2007. View Article : Google Scholar : PubMed/NCBI
22	Adiseshaiah P, Papaiahgari SR, Vuong H, Kalvakolanu DV and Reddy SP: Multiple cis-elements mediate the transcriptional activation of human fra-1 by 12-O-tetradecanoylphorbol-13-acetate in bronchial epithelial cells. J Biol Chem. 278:47423–47433. 2003. View Article : Google Scholar : PubMed/NCBI
23	Adiseshaiah P, Peddakama S, Zhang Q, Kalvakolanu DV and Reddy SP: Mitogen regulated induction of FRA-1 proto-oncogene is controlled by the transcription factors binding to both serum and TPA response elements. Oncogene. 24:4193–4205. 2005. View Article : Google Scholar : PubMed/NCBI
24	Gruda MC, Kovary K, Metz R and Bravo R: Regulation of Fra-1 and Fra-2 phosphorylation differs during the cell cycle of fibroblasts and phosphorylation in vitro by MAP kinase affects DNA binding activity. Oncogene. 9:2537–2547. 1994.PubMed/NCBI
25	Hurd TW, Culbert AA, Webster KJ and Tavaré JM: Dual role for mitogen-activated protein kinase (Erk) in insulin-dependent regulation of Fra-1 (fos-related antigen-1) transcription and phosphorylation. Biochem J. 368:573–580. 2002. View Article : Google Scholar : PubMed/NCBI
26	Milde-Langosch K: The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer. 41:2449–2461. 2005. View Article : Google Scholar : PubMed/NCBI
27	Belguise K, Milord S, Galtier F, Moquet-Torcy G, Piechaczyk M and Chalbos D: The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells. Oncogene. 31:4889–4897. 2012. View Article : Google Scholar : PubMed/NCBI
28	Kehrmann A, Truong H, Repenning A, Boger R, Klein-Hitpass L, Pascheberg U, Beckmann A, Opalka B and Kleine-Lowinski K: Complementation of non-tumorigenicity of HPV18-positive cervical carcinoma cells involves differential mRNA expression of cellular genes including potential tumor suppressor genes on chromosome 11q13. Cancer Genet. 206:279–292. 2013. View Article : Google Scholar : PubMed/NCBI
29	Soto U, Denk C, Finzer P, Hutter KJ, zur Hausen H and Rösl F: Genetic complementation to non-tumorigenicity in cervical-carcinoma cells correlates with alterations in AP-1 composition. Int J Cancer. 86:811–817. 2000. View Article : Google Scholar : PubMed/NCBI
30	Missero C and Antonini D: Crosstalk among p53 family members in cutaneous carcinoma. Exp Dermatol. 23:143–146. 2014. View Article : Google Scholar : PubMed/NCBI
31	Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, Espié M and de Thé H: p53 in breast cancer subtypes and new insights into response to chemotherapy. Breast. 22(Suppl 2): S27–S29. 2013. View Article : Google Scholar : PubMed/NCBI
32	Tassone P, Old M, Teknos TN and Pan Q: p53-based therapeutics for head and neck squamous cell carcinoma. Oral Oncol. 49:733–737. 2013. View Article : Google Scholar : PubMed/NCBI
33	Ku JH, Byun SS, Jeong H, Kwak C, Kim HH and Lee SE: The role of p53 on survival of upper urinary tract urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer. 11:221–228. 2013. View Article : Google Scholar : PubMed/NCBI
34	Tornesello ML, Buonaguro L and Buonaguro FM: Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review. Gynecol Oncol. 128:442–448. 2013. View Article : Google Scholar
35	Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li W, Wang F and Wu E: Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer. 48:2328–2338. 2012. View Article : Google Scholar : PubMed/NCBI
36	Mitchell S, Mayer E and Patel A: Expression of p53 in upper urinary tract urothelial carcinoma. Nat Rev Urol. 8:516–522. 2011. View Article : Google Scholar : PubMed/NCBI
37	Nayak SK, Panesar PS and Kumar H: Non-genotoxic p53-activators and their significance as antitumor therapy of future. Curr Med Chem. 18:1038–1049. 2011. View Article : Google Scholar : PubMed/NCBI
38	Xiao S, Zhou Y, Jiang J, Yuan L and Xue M: CD44 affects the expression level of FOS-like antigen 1 in cervical cancer tissues. Mol Med Rep. 9:1667–1674. 2014.PubMed/NCBI
39	Liao S, Xiao S, Zhu G, Zheng D, He J, Pei Z, Li G and Zhou Y: CD38 is highly expressed and affects the PI3K/Akt signaling pathway in cervical cancer. Oncol Rep. 32:2703–2709. 2014.PubMed/NCBI
40	Zhu W, Li J, Su J, Li J, Li J, Deng B, Shi Q, Zhou Y and Chen X: FOS-like antigen 1 is highly expressed in human psoriasis tissues and promotes the growth of HaCaT cells in vitro. Mol Med Rep. 10:2489–2494. 2014.PubMed/NCBI
41	Xiao S, Liao S, Zhou Y, Jiang B, Li Y and Xue M: High expression of octamer transcription factor 1 in cervical cancer. Oncol Lett. 7:1889–1894. 2014.PubMed/NCBI
42	Zhou Y, Wang W, Zheng D, Peng S, Xiong W, Ma J, Zeng Z, Wu M, Zhou M, Xiang J, Xiang B, Li X, Li X and Li G: Risk of nasopharyngeal carcinoma associated with polymorphic lacto-transferrin haplotypes. Med Oncol. 29:1456–1462. 2012. View Article : Google Scholar
43	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
44	Hara A and Okayasu I: Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance. Acta Neuropathol. 108:43–48. 2004. View Article : Google Scholar : PubMed/NCBI
45	Salehi M, Taheri T, Mohit E, Zahedifard F, Seyed N, Taslimi Y, Sattari M, Bolhassani A and Rafati S: Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model. Immunotherapy. 4:1107–1120. 2012. View Article : Google Scholar : PubMed/NCBI
46	Sahiner F, Gümral R, Sener K, Yiğit N, Dede M, Yapar M and Kubar A: Investigation of HPV-DNA in cervical smear samples by two different methods: MY09/11 consensus PCR and type-specific real-time PCR. Mikrobiyol Bul. 46:624–636. 2012.(In Turkish). PubMed/NCBI
47	Song H, Wu F, Zhang Y, Zhang Y, Wang F, Jiang M, Wang Z, Zhang M, Li S, Yang L, Wang XL, Cui T and Tang D: Irisin promotes human umbilical vein endothelial cell proliferation through the ERK signaling pathway and partly suppresses high glucose-induced apoptosis. PLoS One. 9:e1102732014. View Article : Google Scholar : PubMed/NCBI
48	Yang M, Yang C and Pei Y: Effects of downregulation of SIRT3 expression on proliferation and apoptosis in esophageal squamous cell carcinoma EC9706 cells and its molecular mechanisms. Biomed Mater Eng. 24:3883–3890. 2014.PubMed/NCBI
49	Chumakov PM: Function of the p53 gene: choice between life and death. Biochemistry (Mosc). 65:28–40. 2000.
50	Harris SL and Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene. 24:2899–2908. 2005. View Article : Google Scholar : PubMed/NCBI
51	Chipuk JE and Green DR: Dissecting p53-dependent apoptosis. Cell Death Differ. 13:994–1002. 2006. View Article : Google Scholar : PubMed/NCBI